Resultados de búsqueda - Alan L. Ho

Limitar resultados
  1. 1
    The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent

    The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent por Jayasree S. Nair, Alan L. Ho, Gary K. Schwartz

    Publicado 2012
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  2. 2
    Regulation of Late G<sub>1</sub>/S Phase Transition and APC<sup>Cdh1</sup>by Reactive Oxygen Species

    Regulation of Late G<sub>1</sub>/S Phase Transition and APC<sup>Cdh1</sup>by Reactive Oxygen Species por Courtney G. Havens, Alan L. Ho, Naohisa Yoshioka, Steven F. Dowdy

    Publicado 2006
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  3. 3
    Locally Advanced and Unresectable Cutaneous Squamous Cell Carcinoma: Outcomes of Concurrent Cetuximab and Radiotherapy

    Locally Advanced and Unresectable Cutaneous Squamous Cell Carcinoma: Outcomes of Concurrent Cetuximab and Radiotherapy por Robert M. Samstein, Alan L. Ho, Nancy Y. Lee, Christopher A. Barker

    Publicado 2014
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  4. 4
    Androgen Receptor Signaling in Salivary Gland Cancer

    Androgen Receptor Signaling in Salivary Gland Cancer por Martin G. Dalin, Philip A. Watson, Alan L. Ho, Luc G.T. Morris

    Publicado 2017
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  5. 5
    Correlation of <i>BRAF</i><sup><i>V600E</i></sup> Mutation and Glucose Metabolism in Thyroid Cancer Patients: An <sup>18</sup>F-FDG PET Study

    Correlation of <i>BRAF</i><sup><i>V600E</i></sup> Mutation and Glucose Metabolism in Thyroid Cancer Patients: An <sup>18</sup>F-FDG PET Study por James Nagarajah, Alan L. Ho, R. Michael Tuttle, Wolfgang Weber, Ravinder K. Grewal

    Publicado 2015
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  6. 6
    Inhibition of Mutant GNAQ Signaling in Uveal Melanoma Induces AMPK-Dependent Autophagic Cell Death

    Inhibition of Mutant GNAQ Signaling in Uveal Melanoma Induces AMPK-Dependent Autophagic Cell Death por Grazia Ambrosini, Elgilda Musi, Alan L. Ho, Elisa de Stanchina, Gary K. Schwartz

    Publicado 2013
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  7. 7
    Differential Regulation of Retinoblastoma Tumor Suppressor Protein by G<sub>1</sub> Cyclin-Dependent Kinase Complexes In Vivo

    Differential Regulation of Retinoblastoma Tumor Suppressor Protein by G<sub>1</sub> Cyclin-Dependent Kinase Complexes In Vivo por Sergei A. Ezhevsky, Alan L. Ho, Michelle Becker‐Hapak, Penny K. Davis, Steven F. Dowdy

    Publicado 2001
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  8. 8
    Consistent PLAG1 and HMGA2 abnormalities distinguish carcinoma ex-pleomorphic adenoma from its de novo counterparts

    Consistent PLAG1 and HMGA2 abnormalities distinguish carcinoma ex-pleomorphic adenoma from its de novo counterparts por Nora Katabi, Ronald Ghossein, Alan L. Ho, Snjezana Doğan, Lei Zhang, Yun‐Shao Sung, Cristina R. Antonescu

    Publicado 2014
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  9. 9
    Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype

    Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype por Alan L. Ho, Elgilda Musi, Grazia Ambrosini, Jayasree S. Nair, Shyamprasad Deraje Vasudeva, Elisa de Stanchina, Gary K. Schwartz

    Publicado 2012
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  10. 10
    Aurora B Kinase Regulates the Postmitotic Endoreduplication Checkpoint via Phosphorylation of the Retinoblastoma Protein at Serine 780

    Aurora B Kinase Regulates the Postmitotic Endoreduplication Checkpoint via Phosphorylation of the Retinoblastoma Protein at Serine 780 por Jayasree S. Nair, Alan L. Ho, Archie Tse, Jesse Coward, Haider Cheema, Grazia Ambrosini, Nicholas Keen, Gary K. Schwartz

    Publicado 2009
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  11. 11
    PDGF Receptor Alpha Is an Alternative Mediator of Rapamycin-Induced Akt Activation: Implications for Combination Targeted Therapy of Synovial Sarcoma

    PDGF Receptor Alpha Is an Alternative Mediator of Rapamycin-Induced Akt Activation: Implications for Combination Targeted Therapy of Synovial Sarcoma por Alan L. Ho, Shyamprasad Deraje Vasudeva, Marick Laé, Tsuyoshi Saito, Violetta Barbashina, Cristina R. Antonescu, Marc Ladanyi, Gary K. Schwartz

    Publicado 2012
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  12. 12
    The evolving landscape of salivary gland tumors

    The evolving landscape of salivary gland tumors por Conor Steuer, Glenn J. Hanna, Kartik Viswanathan, James E. Bates, Azeem Kaka, Nicole C. Schmitt, Alan L. Ho, Nabil F. Saba

    Publicado 2023
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  13. 13
    Predictors of Outcome in Adenoid Cystic Carcinoma of Salivary Glands

    Predictors of Outcome in Adenoid Cystic Carcinoma of Salivary Glands por Bin Xu, Esther Drill, Allen S. Ho, Alan L. Ho, Lara Dunn, Carlos Nicolas Prieto-Granada, Timothy A. Chan, Ian Ganly, Ronald Ghossein, Nora Katabi

    Publicado 2017
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  14. 14
    The immune microenvironment and expression of PD‐L1, PD‐1, PRAME and MHC I in salivary duct carcinoma

    The immune microenvironment and expression of PD‐L1, PD‐1, PRAME and MHC I in salivary duct carcinoma por Bin Xu, Achim A. Jungbluth, Denise Frosina, Bayan Alzumaili, Nathaniel Aleynick, Elzbieta Slodkowska, Kevin Higgins, Alan L. Ho, Luc G.T. Morris, Ronald Ghossein, Nora Katabi

    Publicado 2019
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  15. 15
    Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma

    Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma por Vatche Tchekmedyian, Eric J. Sherman, Lara Dunn, Crystal Tran, Shrujal S. Baxi, Nora Katabi, Cristina R. Antonescu, Irina Ostrovnaya, Sofia Haque, David G. Pfister, Alan L. Ho

    Publicado 2019
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  16. 16
    A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

    A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSC... por Lara Dunn, Matthew G. Fury, Han Xiao, Shrujal S. Baxi, Eric J. Sherman, Susan Korte, Christian Pfister, Sofia Haque, Nora Katabi, Alan L. Ho, David G. Pfister

    Publicado 2017
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  17. 17
    Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer

    Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer por Eric J. Sherman, Lara Dunn, Alan L. Ho, Shrujal S. Baxi, Ronald Ghossein, Matthew G. Fury, Sofia Haque, Cami S. Sima, Grace Cullen, James A. Fagin, David G. Pfister

    Publicado 2017
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  18. 18
    Distant metastasis of salivary gland cancer: Incidence, management, and outcomes

    Distant metastasis of salivary gland cancer: Incidence, management, and outcomes por Ximena Mimica, Marlena McGill, Ashley Hay, Daniella K. Zanoni, Jatin P. Shah, Richard J. Wong, Alan L. Ho, Marc A. Cohen, Snehal G. Patel, Ian Ganly

    Publicado 2020
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  19. 19
    Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma

    Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma por Johanna C. Bendell, Valérie André, Alan L. Ho, Ragini R. Kudchadkar, Michael R. Migden, Jeffrey R. Infante, Ramón V. Tiu, Celine Pitou, Trevor Tucker, Les Brail, Daniel D. Von Hoff

    Publicado 2018
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  20. 20
    Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers

    Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers por Brian R. Untch, Vanessa Dos Anjos, María E.R. García-Rendueles, Jeffrey A. Knauf, Gnana P. Krishnamoorthy, Mahesh Saqcena, Umesh Bhanot, Nicholas D. Socci, Alan L. Ho, Ronald Ghossein, James A. Fagin

    Publicado 2018
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:

Herramientas de búsqueda: